Gufic Biosciences Limited (NSE:GUFICBIO)
India · Delayed Price · Currency is INR | Market Cap | 39.92B +3.9% |
| Revenue (ttm) | 9.44B +15.2% |
| Net Income | 642.15M -7.8% |
| EPS | 6.40 -7.9% |
| Shares Out | n/a |
| PE Ratio | 62.17 |
| Forward PE | n/a |
| Dividend | 0.10 (0.03%) |
| Ex-Dividend Date | Sep 22, 2025 |
| Volume | 51,568 |
| Open | 399.00 |
| Previous Close | 396.70 |
| Day's Range | 382.10 - 399.00 |
| 52-Week Range | 268.00 - 448.00 |
| Beta | -0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Gufic Biosciences
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P... [Read more]
Financial Performance
In fiscal year 2026, Gufic Biosciences's revenue was 9.44 billion, an increase of 15.15% compared to the previous year's 8.20 billion. Earnings were 642.15 million, a decrease of -7.80%.
Financial StatementsNews
Gufic Biosciences Transcript: Q4 25/26
Q4 FY 2026 delivered record revenue and profitability, driven by Indore facility ramp-up, strong domestic growth in women's health and aesthetics, and a strategic shift in international business. Margins and revenue are expected to improve further in FY 2027, with stable debt and no major CapEx planned.
Gufic Biosciences Quarterly report: Q4 2026
Gufic Biosciences has published its Q4 2026 quarterly earnings report on June 1, 2026.
Gufic Biosciences Slides: Q4 2026
Gufic Biosciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 1, 2026.
Gufic Biosciences Transcript: Q3 25/26
Q3 FY26 saw flat sequential revenue and EBITDA, with PAT slightly up. Domestic branded business grew modestly, while exports and toxin segments outperformed. Indore plant ramp-up and regulatory progress set the stage for 15-20% growth and margin expansion in FY27.
Gufic Biosciences Quarterly report: Q3 2026
Gufic Biosciences has published its Q3 2026 quarterly earnings report on February 16, 2026.
Gufic Biosciences Slides: Q3 2026
Gufic Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 16, 2026.
Gufic Biosciences Transcript: Q2 25/26
Revenue and margins improved sequentially, driven by Indore facility ramp-up and higher international business mix. Domestic infertility and botulinum toxin divisions showed strong growth, while CMO business is set to recover as more clients transition to Indore.
Gufic Biosciences Quarterly report: Q2 2026
Gufic Biosciences has published its Q2 2026 quarterly earnings report on November 17, 2025.
Gufic Biosciences Slides: Q2 2026
Gufic Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 17, 2025.
Gufic Biosciences Transcript: Q1 25/26
Revenue grew 10% sequentially to INR 226.96 crore, driven by the Indore facility ramp-up and strong export momentum. EBITDA and profit margins improved, with further gains expected as capacity utilization and exports increase. Indore is set to become a margin accretive asset from FY 2027.
Gufic Biosciences Quarterly report: Q1 2026
Gufic Biosciences has published its Q1 2026 quarterly earnings report on August 14, 2025.
Gufic Biosciences Slides: Q1 2026
Gufic Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 14, 2025.